Cordlife collection rates have not recovered to pre-incident levels, but resumption of Singapore operations are ‘encouraging'
[SINGAPORE] Cordlife said that the full resumption of its Singapore operations is an 'encouraging step' in restoring client confidence and regaining operational momentum, even though collection rates remain below average levels from before a storage lapse in December 2023.
The cord blood bank resumed operations earlier this year after the Ministry of Health (MOH) renewed its licences for cord blood banking and human tissue banking services with effect from Jan 14. The ministry had suspended it from carrying out operations after uncovering lapses in the storage of its cord-blood tanks.
In a Friday (Jun 6) business update, the embattled private cord blood bank said that it is continuing to engage customers affected by the incident.
As at May 30, 2025, 56 per cent of affected customers have accepted Cordlife's offers to refund annual fees they paid from the start of the temperature lapse, as well as its offers to waive all subsequent fees for active customers whose children's cord blood units (CBU) are stored in the damaged, high-risk tanks, and to continue storing the CBU of affected customer's children until their child turns 21.
It added that it has received correspondence from clients, assessing the losses resulting from alleged breaches of contract, negligence and misrepresentation, and that it is 'actively monitoring' these matters in consultation with legal advisers and taking steps at appropriate junctures.
To return to pre-incident levels of performance, Cordlife said, it will continue to expand its outreach initiatives in order to maintain a strong sales pipeline.
BT in your inbox
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Sign Up
Sign Up
It sank into the red with a S$6.3 million net loss for its second half ended Dec 31, 2024, reversing from a S$1.3 million net profit in the previous corresponding period, as a result of the fallout from the lapses.
Loss per share for the half-year stood at S$0.0247, from earnings per share of S$0.0051 previously. Its revenue plunged 32 per cent to S$18.7 million, from S$27.4 million, due to the suspension of its Singapore operations until Sep 14, 2024, after the lapses were discovered.
In May this year, the group received a voluntary conditional cash partial offer from Medeze Treasury, a wholly owned subsidiary of Thai-listed stem cell company Medeze Group. The offer was for a 10 per cent stake in the group as Medeze is seeking to explore business opportunities with Cordlife.
The group added that it has been taking 'active steps' to raise public awareness on the importance of cord blood banking and its role in safeguarding future health outcomes by ramping up marketing efforts.
These measures include participating in baby fairs and engaging with the medical community to strengthen its ecosystem of doctors and hospitals.
The group said it has strengthened and renewed relationships with the medical community in Singapore by engaging stakeholders in the community to inform them of its rectification efforts and improved procedures.
It added that it is working closely with the Association for the Advancement of Blood and Biotherapies and the Foundation for the Accreditation of Cellular Therapy to restore its accreditations for Singapore.
Shares of Cordlife ended Thursday 1.9 per cent or S$0.005 higher at S$0.275, before the announcement.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Times
a day ago
- Business Times
Stonepeak said to be in exclusive talks for RM9 billion buyout of Yinson
STONEPEAK Partners is in exclusive talks for a buyout of Yinson Holdings that may value the firm at as much as RM9 billion (S$2.73 billion), according to people with knowledge of the matter, in what could be one of the biggest deals in Malaysia this year. New York-based Stonepeak is teaming up with the Lim family, Yinson's founder and biggest shareholder, to take the Kuala-Lumpur-listed energy infrastructure company private, said the people, asking not to be identified because the discussions aren't public. The Lim family owned 26.6 per cent of Yinson as at May 30. Considerations are ongoing and there is no certainty a deal will be reached, the people said. Yinson's shares jumped as much as 14 per cent following the Bloomberg News report on the talks, the biggest intraday gain since June 2019. That cut the year-to-date loss from 20 per cent as at Thursday's close and lifted Yinson's market value to about RM6.5 billion. Representatives for the Lim family and Yinson declined to comment. Stonepeak didn't immediately respond to requests for comment. Founded in the 1980s as a transport and logistics firm, Yinson has since diversified into energy infrastructure, renewables and technology, its website shows. The company signed an agreement with a consortium of investors in January for a US$1 billion funding round for a unit that makes vessels used by the offshore oil and gas industry, Bloomberg News reported at the time. BLOOMBERG
Straits Times
a day ago
- Straits Times
Manchester United expects annual core profit to return to pre-COVID levels
FILE PHOTO: Soccer Football - Friendly - Hong Kong v Manchester United - Hong Kong Stadium, Hong Kong, China - May 30, 2025 Manchester United players pose for a team group photo before the match REUTERS/Tyrone Siu/File Photo FILE PHOTO: Soccer Football - Europa League - Semi Final - Second Leg - Manchester United v Athletic Bilbao - Old Trafford, Manchester, Britain - May 8, 2025 Manchester United players pose for a team group photo before the match REUTERS/Scott Heppell/File Photo Manchester United raised their annual core profit forecast on Friday to levels last seen before the pandemic as the club's strong performance in the Europa League drove ticket sales and broadcast revenue. Ticket sales jumped more than 50% to 44.5 million pounds in the three months to March as the club had a good run in the Europa League, before losing the finals to Tottenham Hotspur. United's New York-listed shares rose 4.4% in U.S. premarket trading. The club's annual core profit, which excludes player trading and finance cost, is expected to jump 21% to 28% to a range of 180 million to 190 million pounds for the year ending June. United had their worst Premier League season since they were relegated in 1974 and hopes of participating in a European competition next season were dashed after they lost the Europa League final. "We had a difficult season in the Premier League, which we all know fell below our standards and we have a clear expectation of improvement next season," CEO Omar Berrada said in a statement. United's absence from European competitions, which are lucrative sources of broadcasting revenue, deals a huge blow to the club's future finances and has drawn anger and disappointment from fans. Jim Ratcliffe, who holds a stake of about 29% in the club and runs their football operations, has taken steps to revive the club's fortunes, including by cutting jobs, raising ticket prices and stopping free lunches at staff canteens. United reported a net loss of 2.7 million pounds for the three months ended March 31, smaller than the 71.5 million pounds it posted a year earlier. The Glazer family, who own a majority of the club, have faced strong criticism from fans for saddling the club with debt, overspending on players and putting off investments on infrastructure. Manager Ruben Amorim said in May that the club did not need a big squad since they were not playing in the Champions League. In March this year, United announced plans to build a new 2-billion-pound 100,000-seat stadium, next to the existing Old Trafford. REUTERS Join ST's Telegram channel and get the latest breaking news delivered to you.
Business Times
a day ago
- Business Times
Cordlife collection rates still under pre-incident levels, but resumed Singapore operations are ‘encouraging'
[SINGAPORE] Cordlife said that the full resumption of its Singapore operations is an 'encouraging step' in restoring client confidence and regaining operational momentum, even though collection rates have not recovered to average levels from before a storage lapse in December 2023. The cord blood bank resumed operations earlier this year after the Ministry of Health (MOH) renewed its licences for cord blood banking and human tissue banking services with effect from Jan 14. The ministry had suspended it from carrying out operations after uncovering lapses in the storage of its cord-blood tanks. In a Friday (Jun 6) business update, the embattled private cord blood bank said that it is continuing to engage customers affected by the incident. As at May 30, 2025, 56 per cent of affected customers have accepted Cordlife's offers to refund annual fees they paid from the start of the temperature lapse, as well as its offers to waive all subsequent fees for active customers whose children's cord blood units (CBU) are stored in the damaged, high-risk tanks, and to continue storing the CBU of affected customer's children until their child turns 21. It added that it has received correspondence from clients, assessing the losses resulting from alleged breaches of contract, negligence and misrepresentation, and that it is 'actively monitoring' these matters in consultation with legal advisers and taking steps at appropriate junctures. To return to pre-incident levels of performance, Cordlife said, it will continue to expand its outreach initiatives in order to maintain a strong sales pipeline. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up It sank into the red with a S$6.3 million net loss for its second half ended Dec 31, 2024, reversing from a S$1.3 million net profit in the previous corresponding period, as a result of the fallout from the lapses. Loss per share for the half-year stood at S$0.0247, from earnings per share of S$0.0051 previously. Its revenue plunged 32 per cent to S$18.7 million, from S$27.4 million, due to the suspension of its Singapore operations until Sep 14, 2024, after the lapses were discovered. In May this year, the group received a voluntary conditional cash partial offer from Medeze Treasury, a wholly owned subsidiary of Thai-listed stem cell company Medeze Group. The offer was for a 10 per cent stake in the group as Medeze is seeking to explore business opportunities with Cordlife. The group added that it has been taking 'active steps' to raise public awareness on the importance of cord blood banking and its role in safeguarding future health outcomes by ramping up marketing efforts. These measures include participating in baby fairs and engaging with the medical community to strengthen its ecosystem of doctors and hospitals. The group said it has strengthened and renewed relationships with the medical community in Singapore by engaging stakeholders in the community to inform them of its rectification efforts and improved procedures. It added that it is working closely with the Association for the Advancement of Blood and Biotherapies and the Foundation for the Accreditation of Cellular Therapy to restore its accreditations for Singapore. Shares of Cordlife ended Thursday 1.9 per cent or S$0.005 higher at S$0.275, before the announcement.
